196 related articles for article (PubMed ID: 28188332)
1. Adjudication of osteonecrosis of the jaw in phase III randomized controlled trials of denosumab: a systematic review.
de Boissieu P; Kanagaratnam L; Mahmoudi R; Morel A; Dramé M; Trenque T
Eur J Clin Pharmacol; 2017 May; 73(5):517-523. PubMed ID: 28188332
[TBL] [Abstract][Full Text] [Related]
2. Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials.
Boquete-Castro A; Gómez-Moreno G; Calvo-Guirado JL; Aguilar-Salvatierra A; Delgado-Ruiz RA
Clin Oral Implants Res; 2016 Mar; 27(3):367-75. PubMed ID: 25639776
[TBL] [Abstract][Full Text] [Related]
3. Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures.
Pittman K; Antill YC; Goldrick A; Goh J; de Boer RH
Asia Pac J Clin Oncol; 2017 Aug; 13(4):266-276. PubMed ID: 27862983
[TBL] [Abstract][Full Text] [Related]
4. A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer.
Schiodt M; Vadhan-Raj S; Chambers MS; Nicolatou-Galitis O; Politis C; Coropciuc R; Fedele S; Jandial D; Zhang J; Ma H; Saunders DP
Support Care Cancer; 2018 Jun; 26(6):1905-1915. PubMed ID: 29275525
[TBL] [Abstract][Full Text] [Related]
5. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials.
Qi WX; Tang LN; He AN; Yao Y; Shen Z
Int J Clin Oncol; 2014 Apr; 19(2):403-10. PubMed ID: 23605142
[TBL] [Abstract][Full Text] [Related]
6. RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem?
Van den Wyngaert T; Wouters K; Huizing MT; Vermorken JB
Support Care Cancer; 2011 Dec; 19(12):2035-40. PubMed ID: 21203781
[TBL] [Abstract][Full Text] [Related]
7. The relationship of denosumab pharmacology and osteonecrosis of the jaws.
Malan J; Ettinger K; Naumann E; Beirne OR
Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Dec; 114(6):671-6. PubMed ID: 23159111
[TBL] [Abstract][Full Text] [Related]
8. Definition and estimation of osteonecrosis of jaw (ONJ), and optimal duration of antiresorptive treatment in bone metastatic cancer patients: supplementary data from the denosumab extension study?
Fusco V; Bedogni A; Addeo A; Campisi G
Support Care Cancer; 2017 Feb; 25(2):345-349. PubMed ID: 26961666
[No Abstract] [Full Text] [Related]
9. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
10. Differences between bisphosphonate-related and denosumab-related osteonecrosis of the jaws: a systematic review.
Querrer R; Ferrare N; Melo N; Stefani CM; Dos Reis PED; Mesquita CRM; Borges GA; Leite AF; Figueiredo PT
Support Care Cancer; 2021 Jun; 29(6):2811-2820. PubMed ID: 33140246
[TBL] [Abstract][Full Text] [Related]
11. An evidence-based review of risk-reductive strategies for osteonecrosis of the jaws among cancer patients.
Kyrgidis A; Tzellos TG; Toulis K; Arora A; Kouvelas D; Triaridis S
Curr Clin Pharmacol; 2013 May; 8(2):124-34. PubMed ID: 23092218
[TBL] [Abstract][Full Text] [Related]
12. Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years.
Watts NB; Grbic JT; Binkley N; Papapoulos S; Butler PW; Yin X; Tierney A; Wagman RB; McClung M
J Clin Endocrinol Metab; 2019 Jun; 104(6):2443-2452. PubMed ID: 30759221
[TBL] [Abstract][Full Text] [Related]
13. Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review.
Raimondi A; Simeone N; Guzzo M; Maniezzo M; Collini P; Morosi C; Greco FG; Frezza AM; Casali PG; Stacchiotti S
ESMO Open; 2020 Jul; 5(4):. PubMed ID: 32661185
[TBL] [Abstract][Full Text] [Related]
14. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
15. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
[TBL] [Abstract][Full Text] [Related]
16. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease.
Sivolella S; Lumachi F; Stellini E; Favero L
Anticancer Res; 2013 May; 33(5):1793-7. PubMed ID: 23645723
[TBL] [Abstract][Full Text] [Related]
17. Teriparatide therapy for denosumab-induced osteonecrosis of the jaw in a male osteoporotic patient.
Neuprez A; Rompen E; Crielaard JM; Reginster JY
Calcif Tissue Int; 2014 Jul; 95(1):94-6. PubMed ID: 24804929
[TBL] [Abstract][Full Text] [Related]
18. Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. A Commentary of the Pivotal Trial by Raje et al. Published on Lancet Oncology.
Fusco V; Campisi G; de Boissieu P; Monaco F; Baraldi A; Numico G; Bedogni A
Dent J (Basel); 2018 Sep; 6(3):. PubMed ID: 30200393
[TBL] [Abstract][Full Text] [Related]
19. [Osteonecrosis of the jaw].
Drozdzowska B
Endokrynol Pol; 2011; 62 Suppl 3():4-9. PubMed ID: 22161980
[TBL] [Abstract][Full Text] [Related]
20. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome.
Yarom N; Yahalom R; Shoshani Y; Hamed W; Regev E; Elad S
Osteoporos Int; 2007 Oct; 18(10):1363-70. PubMed ID: 17598065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
